转移性去势抵抗性前列腺癌的治疗顺序与策略

龚玉雯; 庞阳阳; 景锁世; 彭程; 田跃军; 王志平

doi:10.13201/j.issn.1001-1420.2016.10.026

转移性去势抵抗性前列腺癌的治疗顺序与策略

- 兰州大学第二医院泌尿外科研究所,甘肃省泌尿系疾病研究重点实验室,甘肃省泌尿系疾病临床医学中心(兰州,730030)

详细信息

通讯作者: 王志平,E-mail:erywzp@lzu.edu.cn

中图分类号: R737.25

收稿日期: 2016-07-28

Optimal sequence and combination strategies of metastatic castration-resistant prostate cancer

- Research Institute of Urology,Second Hospital of Lanzhou University,Key Laboratory of Urological Disease of Gansu Province,Gansu Nephro-Urological Clinical Center,Lanzhou, 730030, China

More Information

Corresponding author: WANG Zhiping, E-mail: erywzp@lzu.edu.cn

Received Date: 28 July 2016

摘要

摘要: 我国前列腺癌发病率呈逐年上升趋势,且大多数在发现时已处于中晚期,去势治疗(ADT)是目前治疗进展期前列腺癌的标准治疗方法,但在经历18~24个月的中位有效期之后,几乎所有患者都会激素抵抗大多数患者发展为去势抵抗性前列腺癌(CRPC),并且多数患者伴有骨转移以及远处脏器转移。虽然多西他赛一直作为一线治疗方案,但对于转移性去势抵抗性前列腺癌(mCRPC)的治疗仍然是一大难点。近几年一些新药物的出现,一些大型临床研究的支持,使得对mCRPC的治疗有了很大的突破,但合适的治疗策略、治疗顺序仍有很大的争论。在此篇综述中将对mCRPC的治疗进展做一个探讨,并提出合理的治疗策略。
- 转移性去势抵抗性前列腺癌 /
- 化疗 /
- 靶向治疗 /
- 免疫治疗 /
- 核素治疗
Abstract: The incidence of prostate cancer shows a rising trend and most patients are diagnosed at an advanced stage in China.Androgen deprivation therapy is regarded as the standard treatment for advanced disease,but nearly all of the patients will finally reach a state of castration-resistant prostate cancer (CRPC) with bone and visceral metastasis.Although docetaxel has been used as first-line therapy,the treatment of metastatic castrationresistant prostate cancer (mCRPC) remains a challenge.In recent years,several new therapeutic drugs show a survival benefit in large trials.However,optimal sequence and combination strategies remain controversial.In this review,we summarize the recent progress of the therapy and clinical trials of mCRPC as well as discuss the rational strategies for mCRPC.
- metastatic castration-resistant prostate cancer /
- chemotherapy /
- targeted therapy /
- immunotherapy /
- radionuclide therapy

HTML全文

参考文献(47)

[1]	Center M M,Jemal A,Lortet-Tieulent J,et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol,2012,61(6):1079-1092.
[2]	Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin 2016,66(2):115-132.
[3]	韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[4]	Lassi K,Dawson N A.Emerging therapies in castrateresistant prostate cancer[J].Curr Opin Oncol,2009,21(3):260-265.
[5]	Cookson M S,Roth B J,Dahm P,et al.Castration-resistant prostate cancer:AUA Guideline[J].J Urol,2013,190(2):429-438.
[6]	Berthold D R,Pond G R,Soban F,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J].J Clin Oncol,2008,26(2):242-245.
[7]	Petrylak D P,Tangen C M,Hussain M H,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J].N Engl J Med,2004,351(15):1513-20.
[8]	Berthold D R,Pond G R,Soban F,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J].J Clin Oncol,2008,26(2):242-245.
[9]	Smith M R,Sweeney C J,Corn P G,et al.Cabozantinib in chemotherapy-pretreated metastatic castrationresistant prostate cancer:results of a phase II nonrandomized expansion study[J].J Clin Oncol,2014,32(30):3391-3399.
[10]	James N D,Sydes M R,Clarke N W,et al.Addition of docetaxel,zoledronic acid,or both to first-line longterm hormone therapy in prostate cancer(STAM-PEDE):survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,387(10024):1163-1177.
[11]	De Bono J S,Oudard S,Ozguroglu M,et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J].Lancet,376(9747):1147-1154.
[12]	Shigeta K,Miura Y,Naito Y,et al.Cabazitaxel for castration-resistant prostate cancer[J].Lancet,2011,377(9760):121.
[13]	Mita A C,Denis L J,Rowinsky E K,et al.Phase Iand pharmacokinetic study of XRP6258(RPR 116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors[J].Clin Cancer Res,2009,15(2):723-730.
[14]	Pivot X,Koralewski P,Hidalgo J L,et al.A multicenter phase II study of XRP6258 administered as a 1-h i.v.infusion every 3 weeks in taxane-resistant metastatic breast cancer patients[J].Ann Oncol,2008,19(9):1547-1552.
[15]	De Bono J S,Logothetis C J,Molina A,et al.Abiraterone and increased survival in metastatic prostate cancer[J].N Engl J Med,2011,364(21):1995-2005.
[16]	Fizazi K,Scher H I,Molina A,et al.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301randomised,double-blind,placebo-controlled phase 3 study[J].Lancet Oncol,2012,13(10):983-992.
[17]	Sternberg C N,Castellano D,Daugaard G,et al.Abiraterone acetate for patients with metastatic castrationresistant prostate cancer progressing after chemotherapy:final analysis of a multicentre,open-label,earlyaccess protocol trial[J].Lancet Oncol,2014,15(11):1263-1268.
[18]	Sun Y,Zou Q,Sun Z,et al.Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure:A randomized,double-blind,placebocontrolled phase 3 bridging study[J].Int J Urol,2016,23(5),404-411.
[19]	Ryan C J,Smith M R,Fizazi K,et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302):final overall survival analysis of a randomised,double-blind,placebo-controlled phase 3study[J].Lancet Oncol,2015,16(2):152-160.
[20]	Tran C,Ouk S,Cleegg N J,et al.Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J].Science,2009,324(5928):787-790.
[21]	Scher H I,Fizazi K,Saad F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy[J].N Engl J Med,2012,367(13):1187-1197.
[22]	Beer T M,Tombal B.Ezalutamide in metastatic prostate cancer before chemotherapy[J].N Engl J Med,2014,371(18):1755-1756.
[23]	Evans C P,Higano C S,Keane T,et al.The PRE-VAIL study:primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naïve metastatic castration-resistant prostate cancer[J].Eur Urol,2016,70(4):675-683.
[24]	Bratt O,Haggman M,Ahlgren G,et al.Openlabel,clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer[J].Br J Cancer,2009,101(8):1233-1240.
[25]	Pili R,Haggman M,Stadler W M,et al.Phase II randomized,double-blind,placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer[J].J Clin Oncol,2011,29(30):4022-4028.
[26]	Sternberg C,Armstrong A,Pili R,et al.Randomized,double-blind,placebo-controlled phase iii study of tasquinimod in men with metastatic castration-resistant prostate cancer[J].J Clin Oncol,2016,34(22):2636-2643.
[27]	Small E J,Schellhammer P F,Higano C S,et al.Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T(APC8015)in patients with metastatic,asymptomatic hormone refractory prostate cancer[J].J Clin Oncol,2006,24:3089-3094.
[28]	Higano C S,Schellhammer P F,Small E J,et al.Integrated data from 2randomized,double-blind,placebocontrolled,phase 3trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer[J].Cancer,2009,115(16):3670-3679.
[29]	Kantoff P W,Higano C S,Shore N D,et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].N Engl J Med,2010,363(5):411-422.
[30]	Kantoff P W,Schuetz T J,Blumenstein B A,et al.O-verall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer[J].J Clin Oncol,2010,28(7):1099-1105.
[31]	Fong L,Small E J.Anti-cytotoxic T-lymphocyte antigen-4antibody:the fi rst in an emerging class of immunomodulatory antibodies for cancer treatment[J].JClin Oncol,2008,26(32):5275-5283.
[32]	Fong L,Kwek S S,O'Brien S,et al.Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF[J].Cancer Res,2009,69(2):609-615.
[33]	van den Eertwegh A J,Versluis J,van den Berg H P,et al.Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer:aphase 1 dose-escalation trial[J].Lancet Oncol,2012,13(5):509-517.
[34]	Madan R A,Mohebtash M,Arlen P M,et al.Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer:aphase 1 dose- escalation trial.Lancet Oncol,2012,13(5):501-508.
[35]	Kwon E D,Drake C G,Scher H I,et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043):a multicentre,randomized,double-blind,phase 3trial[J].Lancet Oncol,2014,15(7):700-712.
[36]	Parker C,Nilsson S,Heinrich D,et al.Alpha emitter radium-223and survival in metastatic prostate cancer[J].N Engl J Med,2013,369(3):213-223.
[37]	Liepe K,Kotzerke J.A comparative study of 188ReHEDP,186Re-HEDP,153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases[J].Nucl Med Commun,2007,28(8):623-630.
[38]	Tu S M,Millikan R E,Mengistu B,et al.Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomized phase II trial[J].Lancet,2001,357(9253):336-341.
[39]	Morris M J,Pandit-Taskar N,Carrasquillo J,et al.Phase I study of samarium-153lexidronam with docetaxel in castration-resistant metastatic prostate cancer[J].J Clin Oncol,2009,27(15):2436-2442.
[40]	Fizazi K,Beuzeboc P,Lumbroso J,et al.Phase II trial of consolidation docetaxel and samarium-153in patients with bone metastases from castration-resistant prostate cancer[J].J Clin Oncol,2009,27(15):2429-2435.
[41]	van Dodewaard-de Jong J M,de Klerk J M,Bloemendal H J,et al.A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castrationresistant prostate cancer(CRPC)metastatic to bone(the TAXIUM trial)[J].Eur J Nucl Med Mol Imaging,2011,38(11):1990-1998.
[42]	Tu S M,Mathew P,Wong F C,et al.Phase I study of concurrent weekly docetaxel and repeated samarium-153lexidronam in patients with castration-resistant metastatic prostate cancer[J].J Clin Oncol,2009,27(20):3319-3324.
[43]	Sonpavde G,Bhor M,Hennessy D,Bhowmik D,Shen L,et al.Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer:Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices[J].Clin Genitourin Cancer,2015,13(4):309-318.
[44]	Loriot Y,Bianchini D,Ileana E,et al.Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide(MDV3100)[J].Ann Oncol,2013,24(7):1807-1812.
[45]	Noonan K L,North S,Bitting R L,et al.Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.Ann Oncol,2013,24:1802-1807.
[46]	Schrader A J,Boegemann M,Ohlmann C H,et al.Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.Eur Urol,2014,65(1):30-36.
[47]	Bianchini D,Lorente D,Rodriguez-Vida A,et al.Antitumour activity of enzalutamide(MDV3100)in patients with metastatic castration-resistant prostate cancer(CRPC)pre-treated with docetaxel and abiraterone[J].Eur J Cancer,2013,50(1):78-84.